🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07233317
Starting soon Not applicable

Evaluating the Safety and Effectiveness of a Vascular Interventional Robotic System in Assisting With Percutaneous Coronary Intervention Procedures: A Prospective, Multicenter, Randomized Controlled Clinical Trial

NCT07233317 · tracked via the Priya Life Science China tracker
Sponsor
China National Center for Cardiovascular Diseases
Phase
Not applicable
Started
2025-12-01
Last updated
2025-11-18

Condition(s) studied

Coronary Artery Disease

Investigational drug(s) / intervention(s)

vascular interventional robotic systemhuman operator

vascular interventional robotic system: Patients all undergoing PCI with vascular interventional robotic system

human operator: Patients undergoing PCI by human operators

Study summary

The goal of this clinical trial is to verify the safety and effectiveness of the vascular interventional robotic system developed and manufactured by Beijing Zhongke Hongtai Medical Technology Co., Ltd. in assisting percutaneous coronary intervention procedures in patients with coronary artery disease. The main question it aims to answer is:

1. Whether the PCI-assisted procedure was clinically successful and technically successful?
2. Will the PCI-assisted procedure can reduce procedure time, PCI time, and radiation exposure for both operators and patients?? Researchers will compare the vascular interventional robotic system with human operators to see if using the vascular interventional robotic system in PCI procedure is effective and safe.

Participants will undergo percutaneous coronary interventions with the vascular interventional robotic system or human operator based on the randomization results. Then all participants will receive a 1-month follow up to evaluate the primary and secondary endpoints.

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1.18 years ≤ Age ≤ 80 years; 2.Presence of clinical indications for PCI and requiring PCI treatment; 3.The subject or their legal guardian is able to understand the trial objectives, voluntarily signs the informed consent form, and is willing to comply with follow-up procedures. 4.Visual estimation of target lesion diameter stenosis ≥70% (or ≥50% with clinical evidence of myocardial ischemia); 5.2.25 mm ≤ Visual reference vessel diameter ≤ 4.0 mm; 6.The target lesion can be fully covered by a single stent, with at least 2.0 mm of normal vessel segment at the proximal and distal edges of the lesion; 7.Number of target vessels requiring treatment ≤ 2; one target lesion treated with one stent; staged treatment of the target lesion is not allowed. Exclusion Criteria: 1. Underwent other PCI within 72 hours before the PCI procedure. 2. Underwent PCI within 30 days before the PCI procedure and experienced a Major Adverse Cardiovascular Event (MACE). 3. Experienced acute Myocardial Infarction (MI) within one week before the PCI procedure. 4. Experienced cardiogenic shock within 48 hours before the PCI procedure. 5. Had a stroke within 30 days before the PCI procedure. 6. Subjects with active peptic ulcer or upper gastrointestinal bleeding within 6 months before the PCI procedure. 7. Severe heart failure (NYHA Class IV). 8. Pregnant and lactating women, or women planning to become pregnant during the clinical trial period. 9. Known allergy to aspirin, heparin, clopidogrel, contrast agents, metal materials, etc. 10. Patients with acute or chronic kidney disease (e.g., serum creatinine \>2.5 mg/dL or \>221 µmol/L) or on dialysis. 11. Subjects with a history of major bleeding or coagulation disorders within the past 6 months. 12. Subjects currently participating in another clinical study that has not completed the entire follow-up period. 13. The investigator determines that the patient has other conditions unsuitable for PCI assisted by the vascular interventional robotic system. 14. Requiring other treatment modalities (such as rotational atherectomy or laser therapy) in addition to balloon angioplasty and stent angioplasty. 15. Presence of more than two lesions in a single vessel requiring simultaneous treatment. 16. Presence of visible thrombus. 17. The target lesion is located in the left main coronary artery. 18. Severely tortuous lesions, severely calcified lesions, or other complex vascular conditions deemed by the investigator as unsuitable for PCI assisted by the vascular interventional robotic system.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Fuwai Hospital, Chinese Academy of Medical Sciences Beijing Xicheng District

More China National Center for Cardiovascular Diseases trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07233317 on ClinicalTrials.gov ↗ ← All trials in China